job_11 OP : Checked and found that the original grant given to the employee was on 27 February 2024, which is 1 year ago, and due to subsequent reverse stock splits, which the company had done 2 splits in 2024, the stock splits have adjusted this exercise price upward to it current amount which is $1,777.60.

job_11 OP blessings u : TNX-102 SL's impact on sleep quality has been evaluated in multiple Phase 3 clinical trials, not just Phase 2 studies. These Phase 3 trials have demonstrated significant improvements in sleep quality among participants.
For instance, in the RESILIENT Phase 3 trial, TNX-102 SL met its primary endpoint by significantly reducing daily pain compared to placebo. Additionally, it showed statistically significant improvements in all six key secondary endpoints, including sleep quality, reduced fatigue, and enhanced overall fibromyalgia symptoms and function.
Similarly, the RELIEF Phase 3 trial reported that TNX-102 SL treatment led to significant reductions in daily pain and was associated with improvements in sleep quality.